No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Xenetic Biosciences Extends Research Agreement With University of Virginia For Advancement Of DNase-Based Oncology Platform
Xenetic Biosciences Presents Preclinical Data On DNase I Co-Administration With CAR T Cells, Highlighting Potential To Enhance Therapeutic Responses In Melanoma Lung Metastasis Model
Xenetic Biosciences GAAP EPS of -$0.28, Revenue of $614.1M
8-K: Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
10-Q: Q3 2024 Earnings Report
H.C. Wainwright Maintains Xenetic Biosciences(XBIO.US) With Hold Rating
Unlock the Full List